Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$121.78 USD

121.78
3,374,078

-1.04 (-0.85%)

Updated Jul 12, 2024 03:29 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Glaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant

Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.

Sanghamitra Saha headshot

5 Reasons to Bet on Growth ETFs

A few upbeat developments on the vaccine front, unprecedented economic help, reopening of economies and a few bullish economic datapoints should facilitate growth stocks ahead.

    Sanghamitra Saha headshot

    5 High Beta ETFs That Are in High Momentum

    Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta ETFs that are in high momentum should gain ahead.

      Sweta Jaiswal, FRM headshot

      Biotech ETFs Soaring on COVID-19 Vaccine Progress

      Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.

      The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

      The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

      Sweta Killa headshot

      Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain

      The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.

      Sreoshi Bera headshot

      5 Health Care Stocks to Bet on as Coronavirus Woes Linger

      The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

      Uptick in Consumer Confidence Puts 3 Stocks on Top

      Consumer Confidence rose for the first time since February, reflecting Americans' optimism as the economy reopens.

      Nalak Das headshot

      Dow Touches 25,000 in More Than 2 Months: 4 Blue-Chip Picks

      The blue-chip index's northbound journey began on Mar 24 and is continuing barring occasional fluctuations.

      Sanghamitra Saha headshot

      Here's How Americans Are Regaining Confidence: 5 Picks

      U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.

        Sweta Killa headshot

        5 Best Stocks of Dow ETF From Last Week

        The Dow Jones gained 3.3% last week, marking its best weekly performance since April 9.

        The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline

        The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline

        Stock Market News for May 26, 2020

        U.S. stocks ended mostly mixed on May 22, as investors tried to fathom the extent of U.S.-China tensions that rose earlier in the week.

        Kinjel Shah headshot

        Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial

        As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.

        Zacks.com headshot

        Novavax Begins Clinical Study for Coronavirus Vaccine

        Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.

        Tirthankar Chakraborty headshot

        2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks

        As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.

        Sanghamitra Saha headshot

        Tap the Solid Momentum in These 5 Solid High-Beta Stocks

        Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.

        Sanghamitra Saha headshot

        Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

        Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

        Ritujay Ghosh headshot

        Coronavirus Vaccine Development Gathers Steam: 4 Winners

        Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

        Ritujay Ghosh headshot

        Coronavirus Vaccine Race Pushes Up Pharma Giants' Production

        Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.

        Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

        Is (MRNA) Outperforming Other Medical Stocks This Year?

        Company News for May 21, 2020

        Companies In The News Are: MRNA, FB, CLX, RCL.

        Sweta Jaiswal, FRM headshot

        Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

        Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

        Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More

        The biotech sector remains in focus with pipeline updates on coronavirus treatments.

        Stock Market News for May 20, 2020

        U.S. stock markets closed lower on Tuesday following the news that a potential vaccine candidate for the treatment of the coronavirus may not be effective.